Improved anti-obesity effect of herbal active and endogenous lipids co-loaded lipid nanocarriers: Preparation, in vitro and in vivo evaluation

Microfluidisation trends in the development of nanodelivery systems: characterisation and release study of resveratrol‐loaded nanostructured lipid carrier prepared with high‐pressure microfluidisation

“…3 a ), with mean diameter value under 200 nm. Besides, NLC system presented a PDI value of ∼0.21 (ranging from 0.18 to 0.23), which expressed a narrow dispersion around the mean particle size and revealed an adequate unimodal behaviour [26]. Noteworthy, the PDI is a parameter referred to PS distribution [11].…”

“…Particles from a colloidal dispersion could adsorb ions or contain groups which can grant charge to nanoparticle surface, reflected by ZP, which plays an important role in physicochemical stability of nanoparticles system [11]. One of the key influences to keep the stability of the lipid nanoparticles delivery systems is to maintain the ZP value of the NLC system displays high level, generally higher than +30 mV or lower than −30 mV, thus forces of repulsion incline to prevent or minimize aggregation of the adjacent charged nanoparticles [11, 26].…”

“…A difference in fatty acid chain lengths of lipids leaded to structural imperfections of matrices and presents extra space for encapsulation of active ingredient. Surfactant can stabilize the formulation and also increase an entrapment of the active ingredient into the lipid matrix of the NLC system [23, 26].…”

“…The active ingredient release rate was speedy in the preliminary period, and then remained at a steady and lower degree. There are different factors that can impact the release of an active ingredient from a delivery system, for example solubility of active substance in the oil phase, its partition coefficient, lipid core internal arrangement, PS and so on [26]. The encapsulation of the NLC leaded to slow release as compared with the free active component solution [31].…”

A New Approach in the Induction of Labor with Misoprostol Vaginal Insert in High-Risk Pregnancy Obese Women

“…The obesity prevalence is increasing progressively during the last ten years in alarming figures [22]. A large meta-analysis on over one million pregnancies (Goldstein, 2017) showed that 47% of pregnant women have a higher gestational weight gain than the recommended figures [23], 17.3% of pregnant women are obese, generating potential higher incidence of maternal and fetal complications [24,25].…”